Lunai Bioworks (LNAI) Return on Sales (2013 - 2026)

Lunai Bioworks (LNAI) posted quarterly Return on Sales of 0.76% for Q1 2026, up 98.48% quarter-over-quarter from 49.93% in Q2 2016.

Lunai Bioworks (LNAI) Return on Sales (2013 - 2026) Analysis & Trends

Lunai Bioworks' Return on Sales history runs 3 years deep, the most recent figure standing at 0.76% for Q1 2026.

In Q1 2026, Return on Sales changed N/A year-over-year to 0.76%; the TTM figure through Mar 2026 stood at 15.65% (changed N/A YoY), while the FY2016 annual figure was 0.51%, changed N/A from the prior year.
Return on Sales for Q1 2026 stood at 0.76%, up from 49.93% in the prior quarter.
The five-year high for Return on Sales was 0.76% in Q1 2026, with the low at 0.76% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	140.52 Bn	132.67 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	86.54 Bn	78.55 Bn	3.93 Bn	0.00%
3	Argenx Se	65.31 Bn	60.13 Bn	1.37 Bn	0.00%
4	Moderna	61.77 Bn	56.64 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	42.26 Bn	37.16 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.19 Bn	27.88 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.71 Bn	10.31 Bn	668.28 Mn	0.00%
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.35 Bn	26.52 Bn	-	0.00%
10	Lunai Bioworks	7.03 Mn	3.87 Mn	20,942.00	-0.76%

Download Data